For the first time in decades, novel urinary tract infection (UTI) treatments and vaccines are making significant progress worldwide.
Recce Pharmaceuticals Ltd today announced positive data from a Phase I/II clinical trial for UTIs and urosepsis, demonstrating that RECCE® 327 (R327) administered intravenously is safe and efficacious against Escherichia coli (E. coli).
Read More
